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Supercritical fluids in biomedical and tissue
engineering applications: a review
A. R. C. Duarte*1,2, J. F. Mano1,2 and R. L. Reis1,2
Over the past several years, the definition of a scaffold for tissue engineering has changed
dramatically, from a material that acts only as an inert structural support for cell attachment to
serving as a more complex and dynamic environment for tissue development. This paper is a
review on the existing and on the new emerging techniques based on supercritical fluid
technology for the preparation of scaffolds and particles for tissue engineering applications.
Supercritical fluid technology has already proven to be feasible for many pharmaceutical
applications and is now emerging as an alternative to conventional materials’ processing methods
for the preparation of three-dimensional structures and injectable particles suitable to be used in
regenerative medicine. The basic principles underlying each technique are here presented as
well as the advantages and disadvantages of each process. The state of the art is reviewed and
the major conclusions of the studies reported in the literature are discussed.
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Introduction
Tissue engineering is a promising therapeutic approach
that combines cells, biomaterials, and bioactive com-
pounds.1,2 The emerging next generation of engineered
tissues relies on the development of loaded scaffolds
containing bioactive molecules in order to control the
cellular function (e.g. growth or differentiation factors)
or to act on the surrounding tissues (e.g. drugs such as
anti-inflammatory agents or antibiotics).3,4 Hence, the
strategy is to mimic matrix and provide necessary
information or signaling for cell attachment, prolifera-
tion and differentiation to meet the requirement of
dynamic reciprocity for tissue engineering.
The potential use of supercritical fluids (SCFs) for
process improvements has led to an increasing interest in
this technology over the past decade. The properties of
these fluids, which can change between those of liquid
and gas depending on the fluid density have been
explored in a number of different techniques, such as
extraction, impregnation, fractionation, adsorption,
chromatography and crystallisation. Supercritical fluids
can also serve as a reaction media in polymerisation or
simply as a processing fluid in particle formation or
foaming. Some techniques have already become com-
mercial namely extraction, e.g. decaffeination, polymer-
isation and foaming. Particle formation is most likely to
be the next major application. The use of SCFs in the
biomedical area, namely in tissue engineering is one of
the newest applications which has emerged in the paste
few years and this review will focus on the work that has
been developed in this field.
Supercritical fluids: basic principles
A substance exists in nature in either one of the three
states of the matter: solid, liquid or gaseous. On a phase
diagram of a pure substance these phases are defined by
the phase boundaries. Nevertheless, beyond the so called
critical point a dense phase occurs and the substance is
said to be in a supercritical state. An SCF can be defined
as a dense phase, which pressure and temperature are
above its critical point (Fig. 1). At the critical point a
single phase exists with properties common to the
liquids, namely density, and common to the gases,
such as viscosity, compressibility and mass diffusion
coefficient.5
The density values of the SCF enable the solvation
power and the lower viscosities induce a higher
diffusivity, thus facilitating mass transfer.6 Different
SCFs are available but not all are suitable for the same
applications. The choice of the SCF depends greatly in
its physico-chemical properties (Table 1).7
Carbon dioxide is the most commonly used SCF as its
critical parameters, specially its low critical temperature,
make it very attractive for the processing of thermo-
sensitive compounds, such as pharmaceuticals and other
bioactive compounds. It presents other important
advantages, since it is environmentally benign, non-
toxic, non-flammable, non-corrosive, readily available
and inexpensive. Furthermore, carbon dioxide has the
status of a GRAS solvent, i.e. it is a generally regarded
as safe solvent. Its elimination and the recovery of final
products are easier in respect to conventional processes
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(no residue is left and a dry solid product is easily
obtained, just by manipulating pressure), leading to
processes with less energy consumption. Carbon dioxide
can be recovered and reused, and therefore, does not
contribute to the greenhouse effect.
As in products for medical and pharmaceutical
applications, the presence of residual organic solvents
is being rigorously controlled by international safety
regulations, it is necessary to warrant the complete
removal and absence of these substances, without
exposing drugs to high temperatures, which may
degrade them.8 Thus the use of SCF technology, namely
using supercritical carbon dioxide appears as a very
interesting alternative to the traditional processing
methods.
Particle formation
Although three-dimensional (3D) porous structures
have been recognised as the most appropriate to sustain
cell adhesion, several applications in tissue engineering
may take advantage of other designs. Injectable systems
that can simultaneously act as scaffolds and delivery
devices are becoming more and more attractive in this
field, especially due to their non-invasive approach.9–11
Materials in particulate form for tissue engineering
have been reviewed by Silva and co-authors in two
papers where the basic concepts and the applications to
bone regeneration are described.12,13 There is no doubt
that tissue engineering strategies are moving towards
systems that are able to combine materials, cells and
growth factors. Materials in particulate form can play a
role in this strategy as carriers for biologically active
molecules. Furthermore, a better control in parameters
such as porosity, pore size, surface area and mechanical
properties can be attained in the case of materials in
particulate form.
In this sense, particle formation using SFC technology
might see exciting perspectives. Supercritical fluid
technology comprises several processes, leading to very
different particles in terms of size, shape and morphol-
ogy that offer various possibilities to address the
different issues to be solved and to prepare various
forms or formulations. The possibility of producing very
small particles with a narrow size distribution using mild
and inert conditions represents a major improvement
over the conventional processes.
Different particle formation processes based on
SFCs are available, including precipitation using the
SFC as non-solvent and precipitation from supercritical
solutions.
In the supercritical antisolvent (SAS) process, also
referred in the literature as ASES, PCA or SEDS, the
solute(s) are dissolved in an organic solvent, which is
contacted with a supercritical solvent (Fig. 2). The
principle of this process is to decrease the solvent power
of the liquid by addition of an antisolvent in which the
solute is insoluble.
The SAS technique presents several advantages,
namely the fact that particles in the nanometre scale
can be produced with easily controlled particle size and
morphology. It is applicable to a wide range of materials
and the processing can be conducted at near ambient
temperatures. Therefore, this technique is good for
processing small amounts of high added value products.
On the other hand it presents some disadvantages, such
as the use of organic solvents, even though it involves
small volumes. For this reason, residual solvent might be
present in the product and the separation of the gas and
solvent may be required at industrial level, which makes
the scale up of the process difficult.
This technique is largely applied in pharmaceuticals,
namely for the preparation of dry inhalable powders,
nanoparticle suspensions, microspheres or microcap-
sules of drug embedded in a carrier, among others.14
However, few studies using this technique have been
reported in the literature for applications in tissue
engineering. Vega-Gonza´lez and co-workers15,16
described the preparation of a fibrous network of poly-
L-lactic acid (PLLA), polymethylmethacrylate (PMMA)
and a blend of poly-e-caprolactone (PCL) with PMMA
using the SAS precipitation process. Systems involving
high molecular weight compounds may cause mass
transfer limitations for the formation of discrete
particles and fibres can be produced. As a result an
Table 1 Critical properties of the most common SFCs
Critical temperature
Tc, K
Critical pressure
pc, bar
Carbon dioxide 304 74
Water 647 221
Ethane 305 49
Ethane 282 50
Propane 370 43
Xenon 290 58
Ammonia 406 114
Nitrous oxide 310 72
Fluoroform 299 49
2 Schematic representation of SAS process: com-
pound(s) are dissolved in organic solution; SCF acts
as antisolvent promoting precipitation of solute
1 Phase diagram of pure substance
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interconnected structure with potential applications in
tissue engineering, which combines macro- and meso-
pores with a rough surface and high surface area is
formed. The same authors have described a modification
of the PCA (particles from a compressed antisolvent) to
prepare composites of a polymer blend of PMMA/PCL
with inorganic particles of titanium dioxide and poly-
(lactic acid) (PLA) with hydroxyapatite nanoparticles. A
3D network of nanofibres was constructed with poten-
tial applications as scaffolds in tissue engineering.17
Figure 3a represents as an example polymeric blends
of PLA and polyethylene glycol (PEG) processed by
SAS. Natural origin polymers may also be processed
using this technique. Costa and co-workers report
the successful precipitation of particles from poly(3-
hydroxybutyrate-co-3-hydroxyvalerate) (PHBV).18
Figure 3b shows PHBV particles precipitated from a
dicloromethane solution.
Another technique widely used for particle formation
is the so called PGSS, particles from gas saturated
solutions. In this case, the compound(s) are melted in
presence of a compressed gas and the liquid is pulverised
towards a low pressure vessel (Fig. 4).
This process has a number of advantages, which make
it very attractive for industrial purposes. It does not
require the use of organic solvents, has a low pressure of
operation and therefore a low SCF consumption. It has
a high production capacity and can be easily scaled up.
The major drawback of PGSS is the fact that it might
have limited applications for pharmaceutical applica-
tions, depending on the operating temperature.
This technique has been studied particularly for the
preparation of fibres and particles that may encapsulate
bioactive molecules. The encapsulation of sensitive
molecules, such as proteins has been successfully
achieved using this process. Lysozyme, ribonuclease,
insulin and calcitonin are examples of proteins processed
with PGSS with minimal loss of their activity.19 This
study proves that SCF mixing can be an alternative to
the current processing options for protein loaded
controlled release devices as it is solvent free, does not
generate solvent/water interfaces and changes in the
kinetics of carbon dioxide depressurisation, can lead to
materials of variable density and surface roughness.
The choice on the supercritical technique to be used
for particle formation depends on the characteristics of
the material to be processed but also on the purpose and
the morphology desired for the particles. It should be
noted however that particle size depends greatly on the
systems processed and, particularly, on the diameter of
the nozzle used for processing. Some materials can be
processed either by SAS or PGSS. In these cases the
technological features (Table 2) of each of the processes
should be taken into account. This is especially
important when an industrial process is planned.
Preparation of 3D scaffolds
One of the most important stages of tissue engineering is
the design and processing of a porous 3D structure, with
high porosity, high interconnectivity between the pores
and uniform distribution made form a biodegradable
polymer or composite. Several techniques are reported
in the literature for the preparation of 3D scaffolds.20
Conventionally, 3D structures can be obtained by
processes such as solvent casting – particle leaching,21
freeze drying – particle leaching,22 thermally induced
phase separation,23 compression moulding,24 injection
moulding,25,26 extrusion,27 foaming,28 wet spinning29
and electrospinning,30 among others.31 The advantages
of these processes have, however, to be weight against
the fact that these normally involve the use of large
amounts of organic solvents, and further purification
and drying steps are often needed. Additionally, some of
these techniques are performed at high temperatures,
which may degrade thermolabile components, such as
3 Image (SEM) of a PLA/PEG and b PHBV microparticles prepared by SAS
4 Schematic representation of PGSS process: SCF is dis-
solved in melted solution which is expanded into a low
pressure vessel
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pharmaceutical drugs and bioactive agents. For these
reasons there is the need to develop new technologies
that are able to avoid or reduce the use of organic
solvents and that operate at mild conditions are of great
interest. Supercritical fluid technology appears to be an
alternative to the conventional processes and several
techniques are described in the literature for processing
of biopolymers and biomedical devices. From the
techniques available, the most commonly used for the
preparation of 3D scaffolds for tissue engineering
purposes include gas foaming and phase inversion
processes.
Gas foaming
One of the most commonly used process for polymeric
foaming is the so called thermally induced phase separa-
tion, where the blowing agent is usually an organic
solvent like pentane. Other methods of preparing poly-
meric foams are available, such as foaming by means of
a chemical foaming agent or by casting and leaching,
where the porogen is usually a water soluble salt. The
main drawbacks of the conventional methods are the
possibility of leaving unwanted contaminations in
the polymeric foams, such as residual solvents and salts,
or the emission of harmful solvents.32
Gas foaming is a good alternative to these processes
as no organic solvents or chemicals are used. Instead,
nitrogen or carbon dioxide are used as blowing agents.
When carbon dioxide is used one can take advantage of
its plasticising properties. In this technique, the polymer
is exposed to carbon dioxide, which plasticises the
polymer by reducing the glass transition temperature.
On venting the CO2 by depressurisation, thermody-
namic instability causes supersaturation of the carbon
dioxide dissolved in the polymer matrix and hence,
nucleation of cells occurs (Fig. 5).33
The main requirement of the CO2 foaming process is
that CO2 can be dissolved in a sufficient amount in the
polymer. This excludes for instance, the use of polymers
which have a very low affinity for CO2. Therefore, this
technique may not be used in polymers with high
crystallinity or high glass transition temperatures and is
more commonly applied to amorphous polymers.
A patent by de Ponti et al.34 describes the foaming of
PLGA using supercritical carbon dioxide (scCO2). In
general, it appears that milder process conditions are
favourable for a high porosity. Mooney and co-workers
first described the used of supercritical foaming for the
preparation of macroporous scaffolds for tissue engi-
neering applications.35,36 In their work, the possibility of
producing matrices with porous surfaces and intercon-
nected pore structrures of PD,LLGA was evaluated and
very promising results were obtained.
In fact, much of the research that has been carried out
in this field is based on homopolymers and copolymers
of lactic and glycolic acids as they are attractive
candidates for the fabrication of tissue engineering
scaffolds.37 Furthermore, they present unique physical
properties that allow them to be processable by this
technique (Table 3).38
Tai and co-workers39 reported a very complete study
on the effect of operating conditions in pore size and
structure of tissue engineering scaffolds prepared with
different blends of PD,LLA and PLGA. The authors
concluded that indeed the pore size and the structure of
the scaffolds could be tailored just by tuning the
processing conditions. This conclusion is of utmost
importance in order to develop scaffolds with the desired
characteristics.
Different successful studies are described in the
literature. Mathieu et al.40 prepared bioresorbable
ceramic polymer composites and demonstrated the
flexibility of gas foaming to produce structures with a
wide range of applications. Furthermore, biocompat-
ibility studies demonstrated that PLA and PLA/HA
(hydroxyapatite) scaffolds allow cell proliferation and
differentiation. Georgiou et al.41 report another work
performed with the aim of re-enforcing scaffolds for
5 Schematic representation of SFC foaming process:
polymer is saturated with CO2 under supercritical con-
ditions followed by rapid depressurisation to atmo-
spheric pressure
Table 2 Technological features of SAS and PGSS processes
SAS PGSS
Process Semicontinuos Continuous
Role SCF Antisolvent Solute
Gas demand Medium Low
Pressure Low to medium Low to medium
Organic solvent Yes Non
Volume of pressurised equipment Medium to large Small
Separation gas/solid Easy Easy
Separation gas/solvent Difficult Not applicable
Table 3 Physical properties of synthetic biodegradable polyesters used as scaffolds for tissue engineering
Poly(gycolic acid) Poly(L-lactic acid) Poly(e-caprolactone)
Tm, uC 230 170 60
Tg, uC 36 56 260
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tissue engineering applications. In that work, composite
scaffolds of PLA and phosphate glass were prepared.
Another study proposes the use of PLGA 50 : 50 and
PLGA 85 : 15 (wt-%) as scaffolds for liver tissue
regeneration. The sponges were produced by CO2 gas
foaming and the main goal was to create a substrate to
grow human hepatoma cell line (Hep3B).42
Another polymer, which can be processed by gas
foaming and that has potential application in the
biomedical area is PCL. Microcellular foams of PCL
have been prepared and are reported by Jenkins
et al.43 Leonard and co-workers44 also report a study
on the characterisation of porous structures of biode-
gradable scaffolds using supercritical carbon dioxide as
a foaming agent and in their study they conclude that
the structure obtained is more homogeneous when the
foaming process is performed at pressures higher than
250 bar.
Recently, supercritical gas foaming has been described
to prepare porous and interconnected structures from
chitin hydrogels.45 The work of Tsioptsias et al. reports
for the first time the ability of carbon dioxide to foam
hydrogels. It was found that the dissolution of carbon
dioxide in the gel is the mechanism that governs the
production of a porous matrix. The same methodology
was applied for the preparation of micro- and nano-
porous composite materials of cellulose.46 In this study,
novel cellulose–composite porous materials were pro-
duced from hydrogels and alcogels. This technique can
also be applied for the preparation of composite
materials, such as cellulose hydroxyapatite constructs.47
Supercritical foaming has also been reported to
prepare PCL scaffolds impregnated with active agents.48
Sudan Red G was selected in this study as a model agent
and it was incorporated in a one step process in the bulk
of the scaffold.
Aydin et al. have described the processing of
polymeric blends.49 In their work, scaffolds of a
copolymer (L-lactic acid and e-caprolactone) have been
successfully prepared by the supercritical assisted foam-
ing process.
The foaming process can also be coupled with other
processing techniques to improve the properties of the
scaffolds prepared. Cellular composites of PLA rein-
forced with glass fibres were prepared in a two step
process.50 A preform of the composite was prepared by
extrusion and fibre bonding and in a subsequent step the
scaffolds were foamed by supercritical gas foaming.
Novel generation of light weight scaffolds with contin-
uous fibres oriented in selective directions can be
therefore prepared.
Another recent study, by Salerno and co-workers,51
presents the possibility of preparing a bimodal PCL
scaffold combining the gas foaming technique and
selective polymer extraction. Results showed that the
combination of these two techniques allow the prepara-
tion of PCL scaffolds with a multiscaled and higly
interconnected microstructure characterised by mechan-
ical properties suitable for load bearing applications.
Velasco and coworkers52 suggested the preparation of
porous polymeric scaffolds incorporating ibuprofen for
tissue engineering of bone and cartilage. Blends of
PMMA–PLA impregnated with the drug have shown
very interesting behaviour in terms of drug release
profile and good biocompatibility.
The gas foaming technique is also a very promising
technique for the preparation of scaffolds loaded with
growth factors and cells. Howdle and coworkers53 have
shown the encapsulation of proteins in biocompatible
and biodegradable polymers such as PLA, PLGA and
PCL is feasible at relatively low temperatures and
moderate pressures.
An attempt to prepare scaffolds with single and dual
protein release from PLA scaffolds was successfully
described by Ginty and co-workers.54 The results
showed that it is possible to control the protein release
profile and distinct release profiles can be obtained for
each protein in the case of dual release. Furthermore,
PLA was blended with PEG to increase the water uptake
of the resultant scaffold and modify the release kinetics
of the encapsulated protein.
The ability to generate porous structures in super-
critical carbon dioxide, which are able to release
angiogenic factors for tissue engineering applications,
was demonstrated by Hile and co-workers who encap-
sulated basic fibroblastic growth factor in PD,LLGA
foams.55 Another work performed by Yang et al.56 used
the same methodology to load the scaffolds with bone
morphogenetic protein 2.
The capacity to deliver growth factors in combination
with appropriate progenitor or stem cells to sites for
tissue regeneration promoting angiogenesis and osteo-
genesis offers therapeutic opportunities in regenerative
medicine. Vascular endothelial growth factor
(VEGF165) was encapsulated in PD,LLA, according to
the technique described and human bone marrow
stromal cells were seeded in the loaded matrixes.57
This study demonstrated the ability to deliver VEGF
from scaffolds with seeded HBMSC to sites of bone
defects with enhanced regeneration of a bone defect.
A non-viral gene delivery system suitable for tissue
engineering applications was developed in a one step
process using gas foaming and carbon dioxide as a
foaming agent.58 DNA complexed with a polyamidoa-
mine cationic polymer was incorporated in PD,LLA. The
results showed that the polyplexes can be released over a
period of two months and a significant gene expression
was achieved during this time.
One of the critical steps in tissue engineering is to
achieve high cell seeding efficiencies. The common
procedure is to deposit or inject cell suspensions into
the scaffolds. The major drawback of this procedure is
the fact that in many situations a large portion of the
cells is washed out or fall down from the scaffold during
the culturing period. A possible way to obtain a more
homogeneous and stable construct would be to process
the material and the cells together. However, cells do not
survive to the processing conditions of most techniques.
Supercritical technologies could provide adequate solu-
tions to overcome these drawbacks. This would be one
of the major advantages of using such technology in the
field of tissue engineering and regenerative medicine.
A recent study reported by Ginty and co-workers59
has shown that mammalian cells can survive in a
supercritical environment up to 5 min. Myoblastic
C2C12 cell line, 3T3 fibroblasts, chondrocytes and
hepatocytes were tested. After this study, the same
group developed a new injection system for the
production of polymer/mammalian cell hybrid
matrixes.60 The technology allows the reduction of the
Duarte et al. SCFs in biomedical and tissue engineering applications
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contact time of the living cells in a supercritical
environment, maximising their viability and function-
ally. Furthermore, this is a single step procedure and the
cells are loaded in the scaffold during its preparation.
Phase inversion
The phase inversion method, also known as immersion
precipitation technique, involves casting of a polymer
solution onto an inert support followed by immersion of
the support with the cast film into a bath filled with a
non-solvent for the polymer. The contact between the
solvent and the non-solvent causes the solution to be
phase separated (Fig. 6). If the non-solvent used is a
SCF this adds several advantages to the process. One of
the most important advantages of the use of carbon
dioxide is the fact that simply by tuning the process
conditions, i.e. pressure and temperature one can tailor
the final structure of the product. Additionally, when
carbon dioxide is used as a non-solvent a subsequent
drying step is avoided and the porous structure obtained
is a dry product free of any residual solvent.
The use of carbon dioxide as a non-solvent for phase
separation has been successfully reported in the litera-
ture for the preparation of different polymeric mem-
branes. Regarding the preparation of porous scaffolds
two polymers largely used for biomedical applications,
PLLA,61 and PMMA62 were processed. Not only porous
matrixes from these two materials were produced but
also composite structures were developed. Tsivintzelis
and co-workers63 report the preparation of nanocom-
posite scaffolds of PLLA with an organomodified
mineral for the reinforcement of the polymeric matrix.
Reverchon et al.64 prepared a drug loaded 3D structure
of PMMA in order to evaluate the feasibility of using
the phase inversion technique for the preparation of
systems able to sustain the delivery of an active
compound. These systems can be used either for tissue
engineering or merely as drug delivery devices.
Recently our group has prepared porous structures of
starch based polymers using this technique. It was for
the first time reported the use of SCF assisted phase
inversion in the processing on natural based polymers.65
The SPLA matrixes prepared by this method are
characterised by a rough surface where micro- and
macropores are visible. Such particular microstructure
enhances the transport properties within the structure
and could also encourage cell attachment and prolifera-
tion. The matrixes are also characterised by a highly
interconnected porous structure. Figure 7 is a represen-
tative image of one of the scaffolds prepared at 150 bar
and 55uC.
The same methodology was used to evaluate the
feasibility of preparing a drug loaded scaffold.
Dexamethasone loaded SPLA scaffolds were prepared
by supercritical assisted phase inversion and the release
could be achieved up to 21 days.66 Furthermore, the
starch based scaffolds were loaded with bioactive glass.
The in vitro bioactivity studies performed on the
synthesised scaffolds have proven that the presence of
bioactive glass can induce the formation of a bone-like
apatite layer, which is very interesting for tissue
engineering applications.67
Temtem and co-workers68 reported the precipitation
of chitosan membranes from an aqueous solution of
dilute acetic acid. Nonetheless, the presence of water and
its poor solubility in the supercritical phase make the
proposed process time consuming and energy intensive.
The feasibility of processing chitosan from organic
solutions was described by Duarte et al.69 Figure 8
represents a cross-section of a chitosan scaffold pre-
cipitated from a 1,1,1,3,3,3- hexa-fluoro-2-propanol
(HFIP) solution. Although organic solvents are used,
the use of scCO2 allow complete solvent removal as CO2
has good diffusivity and mass transfer properties. The
ability of carbon dioxide to diffuse and penetrate in the
bulk of the 3D matrix garantees the complete extraction
of the organic solvent.
Impregnation
In tissue engineering, the development of a scaffold that
can release at controlled rate a biomolecule, maintaining
6 Schematic representation of supercritical assisted
phase inversion process: polymer(s) are dissolved in
organic solution; contact between solvent and SCF that
acts as antisolvent promotes phase separation 7 Image (SEM) of SPLA scaffold prepared by supercriti-
cal assisted phase inversion at 150 bar and 55uC
8 Image (SEM) of chitosan scaffold prepared by supercri-
tical assisted phase inversion at 100 bar and 60uC
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at the same time its biological activity within days or
weeks is of utmost importance. Small molecular weight
drugs that control proliferation and differentiation of
cells can be incorporated into biodegradable scaffolds to
induce cellular differentiation and tissue remodelling.
The scaffold plays, therefore an important role not only
as a physical support but also as a bioactive element able
to address adequate signals to the cells and tissues in the
cell proliferation and differentiation.
The preparation of drug release products necessitates
the use of a mobile phase that dissolves and transports
the drug component, which also swells and stretches the
polymer matrix, facilitating the diffusion of the drug and
increasing the rate of impregnation. The interest on SCF
impregnation process relies on the opportunity to use
the high diffusivity, low surface tension and the ease of
solvent recovery to prepare hybrid supports for tissue
engineering, for long term delivery of therapeutic
molecules, including unstable bioactive compounds,
such as growth factors. Impregnation using SCF tech-
nology has proven to be feasible when the pharmaceu-
tical compound is soluble in carbon dioxide and the
polymer can be swollen by the SCF (Fig. 9). A high
purity product, free of residual solvents is obtained,
since no organic solvents are involved in the impregna-
tion process.70,71 When depressurisation occurs, the gas
rapidly diffuses out of the polymer, deplasticising it and
warranting the complete removal of solvent, without
exposing polymers and bioactive molecules to high
temperatures, which may degrade them.72,73
Supercritical fluid impregnation presents several
advantages when compared to the conventional impreg-
nation processes. It can be easily scaled up, the
therapeutic molecule is homogeneously dispersed within
the matrix due to the excellent diffusivity of carbon
dioxide and the final product is recovered in the dry
state. Nevertheless, this methodology is limited by the
solubility of the drug in the SCF. Although carbon
dioxide is the most commonly used SCF it does have
limitations due to its lack of polarity and its associated
deficiency of specific solvent solute interactions. To
improve polarity/selectivity, it was found that the addi-
tion of small amounts of a so called cosolvent or entra-
iner (usually a polar substance) to an SCF can produce
dramatic effects on its solvent power, some times up to
several hundred percent solubility enhancement.74,75
This impregnation process has been mostly studied for
the preparation of drug delivery systems, which are able
to sustain the drug release within a certain period of time
according to the final purpose of the delivery device.70
Only few studies using this technique have been reported
with the purpose of developing delivery devices for tissue
engineering.
Our group has proven the feasibility of preparing a
loaded chitosan scaffold able to sustain the release of
dexamethasone,76 a steroidal anti-inflammatory agent,
which has been reported to induce effectively differ-
entiation of bone marrow stem cells to osteoblasts,77
including the case when it is directly released inside the
cells.78
Molecules less stable, such as proteins can also be
incorporated into matrixes using SFCs. The impregna-
tion of molecules while minimising any chemical and
structural change in the scaffold is an important
advantage of this technique. Sproule and co-workers79
reported the successful impregnation of a protein in
PMMA scaffolds for biomedical applications. Further-
more, results show that the processing conditions did
not compromise the protein activity. Such kind of results
suggests that it may be possible to load and delivery
growth factors using this technique.
Gong et al.80 used SCF assisted impregnation and
foaming to prepare porous drug PEM/THFM (poly
(ethylmethacrylate)/tetrahydrofurfurylmethacrylate) sys-
tems. This system has shown to have applications, for
example, in cartilage reparation. Another group has
tested the impregnation of polymers prepared by electro-
spinning, namely poly-caprolactone fibres.81 CO2 impre-
gnation of these scaffolds may provide a method for
tailoring the chemistry of these relatively high surface
area scaffolds without altering their biomimetic archi-
tecture. In their work, is reported the impregnation of a
test compound, carboxytetramethylrhodamine and its
release was monitored up to 30 days. The authors
concluded that subcritical CO2 conditions could be used
to embed chemical functionality into tissue engineering
scaffolds without a loss of form.
Chemistry can also be performed impregnating mono-
mers into porous matrixes after its preparation or during
the scaffold processing. This results in scaffolds with
different properties, that may be interesting for parti-
cular applications. For example, Temtem et al.82 have
reported the impregnation of poly(N-isopropylacryla-
mide), PNIPAAm in a chitosan scaffold. In this work, a
chitosan scaffold was used as a matrix for the in situ
polymerisation of NIPA in scCO2. This allows matrixes
to be produced with thermoresponsive capability that
could be used as systems for switchable release of
molecules or smart scaffolds for tissue engineering
applications. Partap and coworkers83 prepared porous
natural synthetic polymer composites using the SFC
assisted impregnation process. Their results suggest that
alginate foams impregnated with hydroxyethyl metha-
crylate are potentially suitable materials in applications
such as tissue engineering scaffolds, where mechanical
conditioning is desired to stimulate cells for develop-
ment of neo tissue growth.
Other techniques
Other techniques have been described in literature for
the preparation of enhanced materials with potential
applications in tissue engineering. This is a very recent
research field and therefore some of these processes are
not extensively studied.
9 Schematic representation of SCF impregnation pro-
cess: SCF saturated with drug component diffuses into
polymeric matrix where drug component is absorbed
and entrapped
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Zhang and co-workers84 reported a new technique for
the preparation of aligned porous materials especially
conceived to serve as scaffolds for aligned nerve growth.
In this process, so called directional freezing of solutions
in liquid CO2, the solute is dissolved in liquid carbon
dioxide and the column is immersed in a liquid nitrogen
bath until it is completely submerged. The gaseous CO2
is sublimed from the sample during slow warming, upon
venting the column, the sample was recovered directly
from the tube as a continuous monolith.
Another research group developed a CO2 assisted
assembly method which offers a process suitable for the
simultaneous assembly of a large number of micro-
nanostructures containing cells and/or biomolecules.85
Yang and coworkers explore the ability of carbon
dioxide to fuse polymeric microstrucutres in an aqueous
environment. Furthermore, the integration of cells and/
or biomolecules in the fabrication process was evalu-
ated. A complex 3D scaffold model impregnated with
mESCs and 3T3 fibroblasts was successfully produced.
Recently, a new SCF assisted process was proposed to
prepare scaffolds for tissue replacement.86 In this
technique a polymeric aerogel is prepared with a solid
porogen and in a subsequent step the gel is dried using
supercritical carbon dioxide. The result is a dry porous
material with potential applications for bone implants.
Surface modification of polymers by graft copolymer-
isation adds unique properties to polymer surfaces,
which may have strong influence in the cell attachment
and proliferation. Grafting of polymer surfaces using
supercritical carbon dioxide has been tested for the
preparation of polyvinylidene fluoride membranes.87
Supercritical CO2, acts as a solvent and carrier agent,
and can accelerate mass transfer of monomers inside
polymer matrixes and facilitate the graft copolymerisa-
tion on the surface of the membrane and within
membrane pores.
The fabrication of microtextured surfaced using a
supercritical assisted technology has been described in
the work of Fujita and coworkers.88 In this work, a new
embossing technique that does not need the use of a
releasing agent or a chemical reaction that may alter the
surface chemistry is described. It is further reported the
feasibility to produce fine substrates of polycarbonate
suitable for evaluating the effect of surface topography
on cell attachment.
Other techniques that present potential for use in the
preparation of 3D structures for tissue engineering
purposes are SCF assisted injection moulding and
extrusion. The extrusion process has so far only been
reported for applications in drug delivery and in the
preparation of controlled delivery devices.89–91
Nonetheless these techniques might see in the future a
new range of applications, namely the preparation of
porous scaffolds with or without bioactive compounds
incorporated.
Conclusions and perspectives
Supercritical fluids appear to be an interesting alter-
native to the conventional processes for the processing
of macromolecules and bioactive compounds in the
context of biomedical applications, including tissue
engineering. Several techniques have been reported in
the literature and the field is continuously growing. As a
reflection of that is the increasing number in papers
published every year.
From the preparation of microparticles to the
development of 3D structures, SCFs have evolved and
present now a wide range of alternative methods that
operate under mild operating conditions and take
advantage of the tunable properties of the fluid phase.
However, any advantage of these processes has always
to be weighted against the cost and inconvenience of the
higher pressures needed.
Different research areas such as polymers precipita-
tion, from gas saturated solutions or using CO2 as an
antisolvent, gas foaming, supercritical assisted phase
inversion, incorporation of bioactive compounds and
cells, surface modification, extrusion and sterilisation
present the current trends of the use of SCF technology
for tissue engineering purposes. The novelty of these
technologies opens a wide range of opportunities for the
preparation of enhanced materials that function not
only as an inert structural support for cell attachment
but act as a more complex and dynamic environment for
tissue development.
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